CDKN2A deletions in acute lymphoblastic leukemia of adolescents and young adults-An array CGH study

Leukemia Research

Volumn 32, Issue 8, 2008, Pages 1228-1235

  Usvasalo, Anu ^a   Savola, Suvi ^b   Räty, Riikka ^c   Vettenranta, Kim ^a   Harila Saari, Arja ^d   Koistinen, Pirjo ^d   Savolainen, Eeva Riitta ^d   Elonen, Erkki ^c   Saarinen Pihkala, Ulla M ^a   Knuutila, Sakari ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

ALL; Array CGH; CDKN2A; Copy number

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; GENE DELETION; GENE LOCUS; GENE TRANSLOCATION; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD;

ADOLESCENT; ADULT; CHILD; FEMALE; GENES, P16; HUMANS; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; SEQUENCE DELETION;

EID: 43049161332     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.01.014     Document Type: Article

References (32)

1. Liggett Jr. W.H., and Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 16 (1998) 1197-1206
2. Kees U.R., Burton P.R., Lu C., and Baker D.L. Homozygous deletion of the p16/MTS1 gene in pediatric acute lymphoblastic leukemia is associated with unfavorable clinical outcome. Blood 89 (1997) 4161-4166
3. Calero Moreno T.M., Gustafsson G., Garwicz S., Grander D., Jonmundsson G.K., Frost B.M., et al. Deletion of the Ink4-locus (the p16ink4a, p14ARF and p15ink4b genes) predicts relapse in children with ALL treated according to the Nordic protocols NOPHO-86 and NOPHO-92. Leukemia 16 (2002) 2037-2045
4. Lee D.S., Lee J.H., Min H.C., Kim T.Y., Oh B.R., Kim H.Y., et al. Application of high throughput cell array technology to FISH: investigation of the role of deletion of p16 gene in leukemias. J Biotechnol 127 (2007) 355-360
5. Heyman M., Rasool O., Borgonovo Brandter L., Liu Y., Grander D., Soderhall S., et al. Prognostic importance of p15INK4B and p16INK4 gene inactivation in childhood acute lymphocytic leukemia. J Clin Oncol 14 (1996) 1512-1520
6. Kuiper R.P., Schoenmakers E.F., van Reijmersdal S.V., Hehir-Kwa J.Y., van Kessel A.G., van Leeuwen F.N., et al. High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression. Leukemia 21 (2007) 1258-1266
7. Mirebeau D., Acquaviva C., Suciu S., Bertin R., Dastugue N., Robert A., et al. The prognostic significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic leukemia of childhood. Results of the EORTC studies 58881 and 58951. Haematologica 91 (2006) 881-885
8. Irving J.A., Bloodworth L., Bown N.P., Case M.C., Hogarth L.A., and Hall A.G. Loss of heterozygosity in childhood acute lymphoblastic leukemia detected by genome-wide microarray single nucleotide polymorphism analysis. Cancer Res 65 (2005) 3053-3058
9. van Zutven L.J., van Drunen E., de Bont J.M., Wattel M.M., Den Boer M.L., Pieters R., et al. CDKN2 deletions have no prognostic value in childhood precursor-B acute lymphoblastic leukaemia. Leukemia 19 (2005) 1281-1284
10. Bertin R., Acquaviva C., Mirebeau D., Guidal-Giroux C., Vilmer E., and Cave H. CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of mono- and bi-allelic 9p21 deletions in childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer 37 (2003) 44-57
11. Ohnishi H., Kawamura M., Ida K., Sheng X.M., Hanada R., Nobori T., et al. Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. Blood 86 (1995) 1269-1275
12. Strefford J.C., Worley H., Barber K., Wright S., Stewart A.R., Robinson H.M., et al. Genome complexity in acute lymphoblastic leukemia is revealed by array-based comparative genomic hybridization. Oncogene 26 (2007) 4306-4318
13. Lukas J., Parry D., Aagaard L., Mann D.J., Bartkova J., Strauss M., et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 375 (1995) 503-506
14. Stott F.J., Bates S., James M.C., McConnell B.B., Starborg M., Brookes S., et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 17 (1998) 5001-5014
15. Weber H.O., Samuel T., Rauch P., and Funk J.O. Human p14(ARF)-mediated cell cycle arrest strictly depends on intact p53 signaling pathways. Oncogene 21 (2002) 3207-3212
16. Hannon G.J., and Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 371 (1994) 257-261
17. Heerema N.A., Sather H.N., Sensel M.G., Liu-Mares W., Lange B.J., Bostrom B.C., et al. Association of chromosome arm 9p abnormalities with adverse risk in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 94 (1999) 1537-1544
18. Merlo A., Herman J.G., Mao L., Lee D.J., Gabrielson E., Burger P.C., et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1 (1995) 686-692
19. Chim C.S., Tam C.Y., Liang R., and Kwong Y.L. Methylation of p15 and p16 genes in adult acute leukemia: lack of prognostic significance. Cancer 91 (2001) 2222-2229
20. Guidal-Giroux C., Gerard B., Cave H., Duval M., Rohrlich P., Elion J., et al. Deletion mapping indicates that MTS1 is the target of frequent deletions at chromosome 9p21 in paediatric acute lymphoblastic leukaemias. Br J Haematol 92 (1996) 410-419
21. Savola S., Nardi F., Scotlandi K., Picci P., and Knuutila S. Microdeletions in 9p21.3 induce false negative results in CDKN2A FISH analysis of Ewing sarcoma. Cytogenet Genome Res 119 1-2 (2007) 21-26
22. Gustafsson G., Schmiegelow K., Forestier E., Clausen N., Glomstein A., Jonmundsson G., et al. Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia 14 (2000) 2267-2275
23. Saarinen-Pihkala U.M., Gustafsson G., Carlsen N., Flaegstad T., Forestier E., Glomstein A., et al. Outcome of children with high-risk acute lymphoblastic leukemia (HR-ALL): nordic results on an intensive regimen with restricted central nervous system irradiation. Pediatr Blood Cancer 42 (2004) 8-23
24. Kaur S., Larramendy M.L., Vauhkonen H., Bohling T., and Knuutila S. Loss of TP53 in sarcomas with 17p12 to approximately p11 gain. A fine-resolution oligonucleotide array comparative genomic hybridization study. Cytogenet Genome Res 116 (2007) 153-157
25. Kaplan E., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 457 (1958) 458-481
26. Peto R., Pike M.C., Armitage P., Breslow N.E., Cox D.R., Howard S.V., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35 (1977) 1-39
27. Perry A., Nobori T., Ru N., Anderl K., Borell T.J., Mohapatra G., et al. Detection of p16 gene deletions in gliomas: a comparison of fluorescence in situ hybridization (FISH) versus quantitative PCR. J Neuropathol Exp Neurol 56 (1997) 999-1008
28. Fizzotti M., Cimino G., Pisegna S., Alimena G., Quartarone C., Mandelli F., et al. Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. Blood 85 (1995) 2685-2690
29. Huang H.Y., Illei P.B., Zhao Z., Mazumdar M., Huvos A.G., Healey J.H., et al. Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol 23 (2005) 548-558
30. Oda Y., Yamamoto H., Takahira T., Kobayashi C., Kawaguchi K., Tateishi N., et al. Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis. J Pathol 207 (2005) 410-421
31. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlations. Br J Haematol 47 (1981) 553-561
32. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33 (1976) 451-458